The global levonorgestrel market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing number of women who are opting for contraceptive methods that do not require daily intake and also due to the increasing awareness about contraceptives among women.
Levonorgestrel Table: The levonorgestrel table segment is expected to account for a significant share in the global levonorgestrel market during the forecast period, owing to its easy availability and low cost. Levonorgestrel Table is available in various doses such as 0.75 mg, 1 mg, 2 mg, 3 mg and 4mg which can be prescribed by doctors depending on their preference or requirement. It has been observed that most doctors prescribe 1mg tablets as it provides effective contraception with minimal side effects when compared with other doses such as 2mg or 3mg tablets which have more side effects like nausea and vomiting etc, but are more effective than lower doses like 0.75mg tablets which have less side effects but are less effective in preventing pregnancy than higher doses such as 1mg or 4mg tablets.
Mixture Products: Mixture products segment accounted for a significant share in the global levonorgestrel market during 2017-2021 owing to its high effectiveness rate when compared with other types of contraceptives such as oral contraceptive pills (OCPs) and intrauterine devices (IUDs). Mixture products include combination pills containing two hormones namely estrogen and progesterone; these hormones work together by suppressing ovulation thereby preventing pregnancy from occurring while also regulating menstrual cycles thereby reducing menstrual cramps etc, OCPs contain only one hormone namely progesterone while IUDs contain no hormones at all; these two types of contraceptives work by preventing fertilization through altering cervical mucus consistency thereby making it difficult for sperm cells to reach an egg cell thus preventing fertilization from occurring; however, they do not regulate menstrual cycles unlike mixture products which regulate both ovulation cycle and menstrual cycle simultaneously hence providing better protection against unwanted pregnancies than OCPs or IUDs respectively.
-The drug has been on the market since 1988 and was approved by the FDA for use in birth control pills in 1993.
-In 2013, it was estimated that about 10 million women were using levonorgestrel as their contraceptive method.
-The drug has been shown to be effective at preventing pregnancy when taken correctly and consistently.
Industry Growth Insights published a new data on “Levonorgestrel Market”. The research report is titled “Levonorgestrel Market research by Types (Levonorgestrel Table, Mixture Products, Hormone-releasing IUD), By Applications (Hospital, Drug Store, Online Sale), By Players/Companies Bayer, Paladin Labs, Foundation Consumer Healthcare, Theramex (Teva), Pfizer, Apotex, HRA Pharma”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Levonorgestrel Market Research Report
By Type
Levonorgestrel Table, Mixture Products, Hormone-releasing IUD
By Application
Hospital, Drug Store, Online Sale
By Companies
Bayer, Paladin Labs, Foundation Consumer Healthcare, Theramex (Teva), Pfizer, Apotex, HRA Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Levonorgestrel Market Report Segments:
The global Levonorgestrel market is segmented on the basis of:
Types
Levonorgestrel Table, Mixture Products, Hormone-releasing IUD
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drug Store, Online Sale
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Paladin Labs
- Foundation Consumer Healthcare
- Theramex (Teva)
- Pfizer
- Apotex
- HRA Pharma
Highlights of The Levonorgestrel Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Levonorgestrel Table
- Mixture Products
- Hormone-releasing IUD
- By Application:
- Hospital
- Drug Store
- Online Sale
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Levonorgestrel Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Levonorgestrel is a progestin hormone that is used as an oral contraceptive. It works by preventing ovulation (the release of an egg from the ovary) and by stopping the growth of the uterine lining. Levonorgestrel also decreases sex hormones in women, which may help to prevent unwanted pregnancy.
Some of the major players in the levonorgestrel market are Bayer, Paladin Labs, Foundation Consumer Healthcare, Theramex (Teva), Pfizer, Apotex, HRA Pharma.
The levonorgestrel market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Levonorgestrel Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Levonorgestrel Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Levonorgestrel Market - Supply Chain
4.5. Global Levonorgestrel Market Forecast
4.5.1. Levonorgestrel Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Levonorgestrel Market Size (000 Units) and Y-o-Y Growth
4.5.3. Levonorgestrel Market Absolute $ Opportunity
5. Global Levonorgestrel Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Levonorgestrel Market Size and Volume Forecast by Type
5.3.1. Levonorgestrel Table
5.3.2. Mixture Products
5.3.3. Hormone-releasing IUD
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Levonorgestrel Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Levonorgestrel Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Drug Store
6.3.3. Online Sale
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Levonorgestrel Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Levonorgestrel Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Levonorgestrel Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Levonorgestrel Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Levonorgestrel Demand Share Forecast, 2019-2026
9. North America Levonorgestrel Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Levonorgestrel Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Levonorgestrel Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Drug Store
9.4.3. Online Sale
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Levonorgestrel Market Size and Volume Forecast by Type
9.7.1. Levonorgestrel Table
9.7.2. Mixture Products
9.7.3. Hormone-releasing IUD
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Levonorgestrel Demand Share Forecast, 2019-2026
10. Latin America Levonorgestrel Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Levonorgestrel Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Levonorgestrel Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Drug Store
10.4.3. Online Sale
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Levonorgestrel Market Size and Volume Forecast by Type
10.7.1. Levonorgestrel Table
10.7.2. Mixture Products
10.7.3. Hormone-releasing IUD
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Levonorgestrel Demand Share Forecast, 2019-2026
11. Europe Levonorgestrel Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Levonorgestrel Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Levonorgestrel Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Drug Store
11.4.3. Online Sale
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Levonorgestrel Market Size and Volume Forecast by Type
11.7.1. Levonorgestrel Table
11.7.2. Mixture Products
11.7.3. Hormone-releasing IUD
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Levonorgestrel Demand Share, 2019-2026
12. Asia Pacific Levonorgestrel Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Levonorgestrel Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Levonorgestrel Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Drug Store
12.4.3. Online Sale
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Levonorgestrel Market Size and Volume Forecast by Type
12.7.1. Levonorgestrel Table
12.7.2. Mixture Products
12.7.3. Hormone-releasing IUD
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Levonorgestrel Demand Share, 2019-2026
13. Middle East & Africa Levonorgestrel Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Levonorgestrel Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Levonorgestrel Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Drug Store
13.4.3. Online Sale
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Levonorgestrel Market Size and Volume Forecast by Type
13.7.1. Levonorgestrel Table
13.7.2. Mixture Products
13.7.3. Hormone-releasing IUD
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Levonorgestrel Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Levonorgestrel Market: Market Share Analysis
14.2. Levonorgestrel Distributors and Customers
14.3. Levonorgestrel Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bayer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Paladin Labs
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Foundation Consumer Healthcare
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Theramex (Teva)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pfizer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Apotex
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. HRA Pharma
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
